சுருக்கம்
Judicious use of antibiotics to minimize emerging resistance: the macrolide clarithromycin as a case study
Joseph Blondeau, Charles K Chan, Ross Davidson Infections remain a major cause of death worldwide and antimicrobial
resistance is increasing. With fewer new antimicrobial agents in development it is imperative
for available antibiotics to last by observing key points: judicious use, appropriate doses
and optimizing regimen compliance in order to reduce the risk of increasing resistance.
This review discusses these issues, using treatment of the respiratory tract pathogen
Streptococcus pneumoniae with the macrolide clarithromycin as a case study. Clarithromycin
is active against common respiratory pathogens achieving high tissue, fluid and serum levels,
and has a relatively short half-life. These characteristics influence the risk of developing
resistance when compared with erythromycin or azithromycin. High local drug concentrations
further reduce the risk of therapeutic failure. Long half-lives associated with a long tail in the
curve of minimum inhibitory concentration (MIC) over time may increase the risk of emerging
was found to be statistically more likely than clarithromycin or erythromycin to select for
organisms with higher MIC values. Poor adherence to antibiotic regimens may accelerate
the development of resistance. Compliance is enhanced by convenient dosing regimens,
for example with extended-release formulations. The ideal antibiotic regimen should achieve
maximal-eradication MIC while minimizing the total time with sub-MICs present in the treated
population, and have mutant prevention concentration values within clinically achievable and
sustainable drug concentrations.
மறுப்பு: இந்த சுருக்கமானது செயற்கை நுண்ணறிவு கருவிகளைப் பயன்படுத்தி மொழிபெயர்க்கப்பட்டது மற்றும் இன்னும் மதிப்பாய்வு செய்யப்படவில்லை அல்லது சரிபார்க்கப்படவில்லை